Atea's polymerase inhibitor fails in late-stage Covid-19 treatment trial

Katherine Lewin

News Reporter

Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment.

The Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Atea's polymerase inhibitor fails in late-stage Covid-19 treatment trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Breaking down silos with a new quantitative approach to drug development

Atea's poly­merase in­hibitor fails in late-stage Covid-19 treat­ment tri­al

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Atea's polymerase inhibitor fails in late-stage Covid-19 treatment trial